BioSpace News Archive

Ironwood Pharmaceuticals, Inc. announced that management will participate in a fireside chat at The JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 1:30 p.m. ET at the New York Hilton Midtown.

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced the closing of its previously announced underwritten public offering of 29,900,000 shares of its common stock, which reflects the exercise in full by the underwriters of their option to purchase up to 3,900,000 additional shares of common stock.

MannKind Corporation reported financial results for the quarter ended March 31, 2023.

AstraZeneca’s FARXIGA (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF.

Researchers at the University of Missouri Laboratory for Infectious Disease Research released the results of a study indicating that electroluminescent film technology, found in widely deployed biometric fingerprint scanners, actively kills SARS-CoV-2.

Basking Biosciences (Basking), a clinical-stage biopharmaceutical company, today discussed the development status of BB-031, the company’s novel, RNA-based thrombolytic for use in patients experiencing acute ischemic stroke, at the Locus Walk RNA Innovation Conference, held virtually.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, announced the appointment of Cynthia Collins to the company’s board of directors.

Evotec SE and Sandoz AG, a division of Novartis announced that Evotec’s Seattle-based subsidiary, Just - Evotec Biologics, Inc., launched a multi-year, long-term tech partnership with Sandoz for the immediate development and subsequent manufacturing of multiple biosimilars.

Prometheus Biosciences, Inc., a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, reported financial results for the quarter ended March 31, 2023.